Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers

Cancer Research
Brian R UntchJ A Fagin

Abstract

Of the three RAS oncoproteins, only HRAS is delocalized and inactivated by farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In this study, we treat mice bearing Hras-driven poorly differentiated and anaplastic thyroid cancers (Tpo-Cre/HrasG12V/p53flox/flox ) with the FTI tipifarnib. Treatment caused sustained tumor regression and increased survival; however, early and late resistance was observed. Adaptive reactivation of RAS-MAPK signaling was abrogated in vitro by selective RTK (i.e., EGFR, FGFR) inhibitors, but responses were ineffective in vivo, whereas combination of tipifarnib with the MEK inhibitor AZD6244 improved outcomes. A subset of tumor-bearing mice treated with tipifarnib developed acquired resistance. Whole-exome sequencing of resistant tumors identified a Nf1 nonsense mutation and an activating mutation in Gnas at high allelic frequency, supporting the on-target effects of the drug. Cell lines modified with these genetic lesions recapitulated tipifarnib resistance in vivo This study demonstrates the feasibility of targeting Ras membrane association in cancers in vivo and predicts combination therapies that confer additional benefit.Significance: Tipifarnib effectively inhibits on...Continue Reading

References

Aug 10, 1990·Science·J LyonsH R Bourne
May 30, 1997·The Journal of Biological Chemistry·D B WhyteJ K Pai
Jul 30, 2004·Genesis : the Journal of Genetics and Development·Takashi KusakabeShioko Kimura
Mar 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Christine A PratilasNeal Rosen
May 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Xu ChenJames A Fagin
Oct 20, 2009·The Journal of Clinical Endocrinology and Metabolism·Marco VolanteYuri E Nikiforov
Apr 27, 2010·Nature Chemical Biology·Frank J DekkerHerbert Waldmann
Jul 7, 2010·Cell·Mark A Lemmon, Joseph Schlessinger
Feb 18, 2011·The Journal of Clinical Endocrinology and Metabolism·Margarida M MouraValeriano Leite
Jul 22, 2011·Science Translational Medicine·Jian WuBert Vogelstein
Jul 23, 2011·Genes & Cancer·Esther Castellano, Eugenio Santos
Oct 25, 2011·Nature Reviews. Cancer·Norbert BerndtSaïd M Sebti
Nov 23, 2011·The Journal of Clinical Investigation·Debyani ChakravartyJames A Fagin
Jan 5, 2013·Cancer Discovery·Steven R WhittakerLevi A Garraway
Feb 14, 2013·British Journal of Cancer·G NishikawaY Kanai
Feb 15, 2013·The New England Journal of Medicine·Alan L HoJames A Fagin
Nov 5, 2013·Nature·Cory M JohannessenLevi A Garraway
Dec 4, 2013·Molecular Cancer Therapeutics·Ellen M BeauchampPeter S Hammerman
Dec 18, 2013·Science·Ophir ShalemFeng Zhang
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 19, 2014·Cancer Discovery·Elza C de BruinJulian Downward
Oct 18, 2014·Nature Reviews. Drug Discovery·Adrienne D CoxChanning J Der
Nov 25, 2014·Cell·UNKNOWN Cancer Genome Atlas Research Network
Jan 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·S Michael RothenbergLori J Wirth
Apr 17, 2015·Nature Reviews. Cancer·Nancy Ratner, Shyra J Miller
Apr 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adrienne D CoxMark R Philips
Jun 24, 2015·Journal of Biochemistry·Fumi ShimaTohru Kataoka
Feb 16, 2016·The Journal of Clinical Investigation·Iñigo LandaJames A Fagin
Nov 4, 2016·Nature Reviews. Drug Discovery·Jonathan M L Ostrem, Kevan M Shokat
Nov 2, 2016·The Journal of Clinical Investigation·James NagarajahJames A Fagin

❮ Previous
Next ❯

Citations

Apr 13, 2019·Endocrine-related Cancer·Miguel A ZaballosPilar Santisteban
Mar 27, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Dapeng ChenXiaochen Dong
Aug 3, 2020·Histopathology·Harsimar B KaurTamara L Lotan
Apr 3, 2019·International Journal of Molecular Sciences·Paola SavoiaOttavio Cremona
Nov 23, 2019·Der Pathologe·R Schäfer
Feb 2, 2019·The Biochemical Journal·Frank McCormick
Jan 29, 2020·Seminars in Cancer Biology·Nikita PozdeyevRebecca E Schweppe
Nov 23, 2020·Current Opinion in Chemical Biology·Ana Losada de la LastraEdward W Tate
Mar 23, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan L HoAntonio Gualberto
Mar 30, 2021·Frontiers in Oncology·Valeria MerzDavide Melisi
May 1, 2021·Genes·Erin Sheffels, Robert L Kortum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.